Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,877 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05152472 | A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments(ATEZOGIST) | recruiting | Phase 2 | 110 | Centre Leon BerardOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05510973 | Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi | completed | N/A | 700 | Elizabeth Glaser Pediatric AIDS FoundationOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT05949099 | Study of Cryoablation and Nirogacestat for Desmoid Tumor | recruiting | Phase 2 | 28 | Nam BuiOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) | recruiting | Phase 2 | 20 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00265798 | Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01189643 | Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | active not recruiting | Early Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02847559 | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | completed | Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809178 | China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm(ChTTSRUIA) | not yet recruiting | — | 608 | Cheng senOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01746238 | Bevacizumab/Doxorubicin/Radiation for Sarcoma | active not recruiting | Phase 1 | 14 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT04577014 | Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 98 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06955169 | Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment(MOMENTUM-1) | recruiting | Phase 2 | 130 | RTOG Foundation, Inc.OTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma(STELLAR-201) | recruiting | Phase 2 | 100 | ExelixisINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07734116 | A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. | recruiting | Phase 1 / Phase 2 | 50 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06644755 | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Daiichi SankyoINDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | suspended | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07459283 | The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors | recruiting | Early Phase 1 | 10 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07613723 | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | recruiting | Phase 1 | 9 | Zelluna Immunotherapy ASINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT00411060 | Clinical Orthopaedic Data Bank (Acute and Chronic) | recruiting | — | 10,000 | University of FloridaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05515575 | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA | active not recruiting | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | terminated | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06073067 | GRID Therapy for Extremity Soft Tissue Sarcoma | recruiting | N/A | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06156410 | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07725380 | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | recruiting | Phase 1 / Phase 2 | 74 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma | not yet recruiting | Phase 1 / Phase 2 | 70 | SOTIO Biotech a.s.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | recruiting | Phase 2 | 124 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04890067 | Observational Study in Localized Osteosarcoma(ISG Os2Oss) | recruiting | — | 120 | Italian Sarcoma GroupNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05837767 | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06904365 | Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women(OvAR-Y) | recruiting | — | 11 | Washington University School of MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07265661 | Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma(STARS) | not yet recruiting | N/A | 142 | Italian Sarcoma GroupNETWORK | 0 | Sep 2, 2026 | clinicaltrials |
| NCT07328425 | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS(ISG-TULIPS) | recruiting | Phase 2 | 20 | Italian Sarcoma GroupNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | completed | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03900793 | Losartan + Sunitinib in Treatment of Osteosarcoma | recruiting | Phase 1 | 41 | University of Colorado, DenverOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04307277 | Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma(CHIC-STS01) | recruiting | Phase 3 | 600 | Institut Claudius RegaudOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06375122 | Natural History Study of Kaposi Sarcoma | recruiting | — | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06898970 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | recruiting | Phase 2 | 18 | Varun Monga, MBBSOTHER | 1 | Sep 1, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials